SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates

Taros Chemicals and Welab Barcelona partner for drug Discovery and development services

The combination will support clients in getting their end-to-end discovery and development programs delivered.

AnaBios acquires Cell Systems to expand human cell portfolio for drug discovery

Teijin and Axcelead to establish drug discovery research JV

The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.

Excelra Partners with HotSpot Therapeutics to enhance allosteric drug discovery efforts

The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI

Iktos and Teijin Pharma to co-develop technology for small molecule drug discovery

Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process

Vipergen’s DNA based drug discovery partnership with Theseus Pharma

Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target